347,764 results match your criteria monoclonal antibody


A mutation in the SAA1 promoter causes hereditary amyloid A amyloidosis.

Kidney Int 2021 Sep 21. Epub 2021 Sep 21.

Research Unit for Rare Diseases, Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University in Prague and General Teaching Hospital in Prague, Czech Republic; Section on Nephrology, Wake Forest School of Medicine, Medical Center Blvd., Winston-Salem, NC, USA. Electronic address:

Amyloid A amyloidosis is a serious clinical condition resulting from the systemic deposition of amyloid A originating from serum amyloid A proteins with the kidneys being the most commonly and earliest affected organ. Previously described amyloid A amyloidosis is linked to increased production and deposition of serum amyloid A proteins secondary to inflammatory conditions arising from infectious, metabolic, or genetic causes. Here we describe a family with primary amyloid A amyloidosis due to a chr11:18287683 T>C (human genome version19) mutation in the SAA1 promoter linked to the amyloidogenic SAA1. Read More

View Article and Full-Text PDF
September 2021

Preparation and Verification of a Monoclonal Antibody against a Conserved Linear Epitope in Enterovirus A Protein 2C.

J Virol Methods 2021 Sep 21:114298. Epub 2021 Sep 21.

Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China. Electronic address:

Enterovirus A (EV-A) species are the main agents responsible for hand, foot, and mouth disease (HFMD), a serious public health concern. Lack of appropriate reagents prevents the mechanistic study of these virus infections. 2C protein, a non-structural protein of Enterovirus, is crucial for viral replication and antiviral immunity. Read More

View Article and Full-Text PDF
September 2021

TGF-β-induced fibrosis: A review on the underlying mechanism and potential therapeutic strategies.

Eur J Pharmacol 2021 Sep 21:174510. Epub 2021 Sep 21.

Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, 43300, Malaysia. Electronic address:

Transforming growth factor-beta (TGF-β) plays multiple homeostatic roles in the regulation of inflammation, proliferation, differentiation and would healing of various tissues. Many studies have demonstrated that TGF-β stimulates activation and proliferation of fibroblasts, which result in extracellular matrix deposition. Its increased expression can result in many fibrotic diseases, and the level of expression is often correlated with disease severity. Read More

View Article and Full-Text PDF
September 2021

In vitro immunization approach to generate specific murine monoclonal IgG antibodies.

J Immunol Methods 2021 Sep 21:113149. Epub 2021 Sep 21.

Institute of Biochemistry and Biology, University of Potsdam, Karl-Liebknecht-Str. 24-25, D-14476 Potsdam, Germany. Electronic address:

Generating a monoclonal antibody to date is a time intense process that requires immunization of laboratory animals. The transfer of the humoral immune response into in vitro settings enables a shortening of this process and circumvents the necessity of in vivo immunization. However, to orchestrate the complex interplay of dendritic cells, T and B lymphocytes in vitro is very challenging. Read More

View Article and Full-Text PDF
September 2021

Cross-neutralization of SARS-CoV-2 by HIV-1 specific broadly neutralizing antibodies and polyclonal plasma.

PLoS Pathog 2021 Sep 24;17(9):e1009958. Epub 2021 Sep 24.

Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.

Cross-reactive epitopes (CREs) are similar epitopes on viruses that are recognized or neutralized by same antibodies. The S protein of SARS-CoV-2, similar to type I fusion proteins of viruses such as HIV-1 envelope (Env) and influenza hemagglutinin, is heavily glycosylated. Viral Env glycans, though host derived, are distinctly processed and thereby recognized or accommodated during antibody responses. Read More

View Article and Full-Text PDF
September 2021

Structurally related but genetically unrelated antibody lineages converge on an immunodominant HIV-1 Env neutralizing determinant following trimer immunization.

PLoS Pathog 2021 Sep 24;17(9):e1009543. Epub 2021 Sep 24.

Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, Washington, United States of America.

Understanding the molecular mechanisms by which antibodies target and neutralize the HIV-1 envelope glycoprotein (Env) is critical in guiding immunogen design and vaccine development aimed at eliciting cross-reactive neutralizing antibodies (NAbs). Here, we analyzed monoclonal antibodies (mAbs) isolated from non-human primates (NHPs) immunized with variants of a native flexibly linked (NFL) HIV-1 Env stabilized trimer derived from the tier 2 clade C 16055 strain. The antibodies displayed neutralizing activity against the autologous virus with potencies ranging from 0. Read More

View Article and Full-Text PDF
September 2021

Population pharmacokinetics of subcutaneous infliximab CT-P13 in Crohn's disease and ulcerative colitis.

Aliment Pharmacol Ther 2021 Sep 24. Epub 2021 Sep 24.

Department of Hospital Pharmacy - Clinical Pharmacology, Amsterdam UMC, Amsterdam, the Netherlands.

Background: Infliximab is a chimeric monoclonal antibody against tumour necrosis factor-alpha for the treatment of Crohn's disease (CD) and ulcerative colitis (UC). Recently, a subcutaneous formulation of CT-P13, an infliximab biosimilar, was approved for clinical use.

Aims: To characterise CT-P13 pharmacokinetics (PK) and its clinically relevant determinants after subcutaneous administration through population PK modelling. Read More

View Article and Full-Text PDF
September 2021

Subcutaneous golimumab induced and maintained clinical response in a child with a biological-experienced steroid-refractory flare of ulcerative colitis: A case report.

Medicine (Baltimore) 2021 Sep;100(38):e27283

Gastroenterology Department, Damascus Hospital, Damascus, Syria.

Introduction: Golimumab is a fully human antitumor necrosis monoclonal antibody that can be administered by either subcutaneous injection or intravenous infusion. Golimumab is approved for the treatment of the adults with rheumatic diseases, and ulcerative colitis, Whereas in children, golimumab is indicated only for the treatment of active polyarticular juvenile idiopathic arthritis. We have written on the off-label use of subcutaneous golimumab, which helped to induce and maintain remission on a low-weight biologically experienced child with steroid-refractory ulcerative colitis flare. Read More

View Article and Full-Text PDF
September 2021

Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient?

J Oncol Pharm Pract 2021 Sep 24:10781552211038136. Epub 2021 Sep 24.

Department of Medical Oncology, 147021University of Health Sciences Ümraniye Training and Research Hospital, Turkey.

Introduction: Nivolumab is a human immunoglobulin G4 monoclonal antibody that inhibits programmed cell death-1 activity by binding to the programmed cell death-1 receptors. Cancer cells express increased number of programmed cell death-1 ligands and this allows them to escape the cytotoxic effects of the T cells. Therefore, the negative programmed cell death-1 receptor signal regulates T-cell proliferation and activation is disrupted. Read More

View Article and Full-Text PDF
September 2021

Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study.

Cancer Med 2021 Sep 23. Epub 2021 Sep 23.

Hematology Department, Hospital Universitario Infanta Leonor, Madrid, Spain.

Background: Lymphoid neoplasms treatment has recently been renewed to increase antitumor efficacy and conventional chemotherapies toxicities. Limited data have been published about the infection risk associated with these new drugs, therefore this study analyzes the infectious complications in patients with lymphoproliferative diseases (LPD) treated with monoclonal antibodies (obinutuzumab, ofatumumab, brentuximab, nivolumab, or pembrolizumab), BTK inhibitors (ibrutinib and acalabrutinib), PI3K inhibitors (idelalisib) and BCL2 inhibitors (venetoclax).

Methods: Multicenter retrospective study of 458 LPD patients treated with targeted therapies in real-life setting, in 18 Spanish institutions, from the time of their commercial availability to August 2020. Read More

View Article and Full-Text PDF
September 2021

Cross-reactive Antibody Response to mRNA SARS-CoV-2 Vaccine After Recent COVID-19-Specific Monoclonal Antibody Therapy.

Open Forum Infect Dis 2021 Sep 10;8(9):ofab420. Epub 2021 Aug 10.

Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

The efficacy of coronavirus disease 2019 (COVID-19) vaccines administered after COVID-19-specific monoclonal antibody is unknown, and "antibody interference" might hinder immune responses leading to vaccine failure. In an institutional review board-approved prospective study, we found that an individual who received mRNA COVID-19 vaccination <40 days after COVID-19-specific monoclonal antibody therapy for symptomatic COVID-19 had similar postvaccine antibody responses to SARS-CoV-2 receptor binding domain (RBD) for 4 important SARS-CoV-2 variants (B.1, B. Read More

View Article and Full-Text PDF
September 2021

New Immunotherapeutic Approaches for Glioblastoma.

J Immunol Res 2021 13;2021:3412906. Epub 2021 Sep 13.

Neurochemistry and Behavior Laboratory, National Institute of Neurology and Neurosurgery "Manuel Velasco Suárez", Mexico City 14269, Mexico.

Glioblastoma (GBM) is the most common primary malignant brain tumor with a high mortality rate. The current treatment consists of surgical resection, radiation, and chemotherapy; however, the median survival rate is only 12-18 months despite these alternatives, highlighting the urgent need to find new strategies. The heterogeneity of GBM makes this tumor difficult to treat, and the immunotherapies result in an attractive approach to modulate the antitumoral immune responses favoring the tumor eradication. Read More

View Article and Full-Text PDF
September 2021

The pharmacoeconomics of the state-of-the-art drug treatments for asthma: a systematic review.

Multidiscip Respir Med 2021 Jan 2;16(1):787. Epub 2021 Aug 2.

Pneumology Unit, Arcispedale Santa Maria Nuova, Azienda USL di Reggio Emilia IRCCS, Reggio Emilia.

Asthma is a chronic disease characterized by significant morbidities and mortality, with a large impact on socio-economic resources and a considerable burden on health-care systems. In the standard care of asthma, inhaled corticosteroids (ICS) associated with long-acting β-adrenoceptor agonists (LABA) are a reliable and often cost-effective choice, especially if based on the single inhaler therapy (SIT) strategy; however, in a subset of patients it is not possible to reach an adequate asthma control. In these cases, it is possible to resort to other pharmacologic options, including corticosteroids (OCS) or biologics. Read More

View Article and Full-Text PDF
January 2021

Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis.

BMJ 2021 Sep 23;374:n2231. Epub 2021 Sep 23.

Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON L8S 4L8, Canada.

Objective: To evaluate the efficacy and safety of antiviral antibody therapies and blood products for the treatment of novel coronavirus disease 2019 (covid-19).

Design: Living systematic review and network meta-analysis, with pairwise meta-analysis for outcomes with insufficient data.

Data Sources: WHO covid-19 database, a comprehensive multilingual source of global covid-19 literature, and six Chinese databases (up to 21 July 2021). Read More

View Article and Full-Text PDF
September 2021

Development of an antigen Enzyme-Linked AptaSorbent Assay (ELASA) for the detection of swine influenza virus in field samples.

Anal Chim Acta 2021 Oct 9;1181:338933. Epub 2021 Aug 9.

Eurofins-Inmunología y Genética Aplicada S.A. (Eurofins-INGENASA), Madrid, Spain.

Influenza viruses are highly variable pathogens that infect a wide range of mammalian and avian species. According to the internal conserved proteins (nucleoprotein: NP, and matrix proteins: M), these viruses are classified into type A, B, C, and D. Influenza A virus in swine is of significant importance to the industry since it is responsible for endemic infections that lead to high economic loses derived from poor weight gain, reproductive disorders, and the role it plays in Porcine Respiratory Disease Complex (PRDC). Read More

View Article and Full-Text PDF
October 2021

Cytometric analysis of patients with COVID-19: what is changed in the second wave?

J Transl Med 2021 Sep 23;19(1):403. Epub 2021 Sep 23.

CEINGE-Biotecnologie Avanzate, via Gaetano Salvatore 486, 80145, Naples, Italy.

Background: Coronavirus disease 2019 (COVID-19) pandemic had a 1st wave in Europe from March to May 2020 and a 2nd wave since September 2020. We previously studied 35 hospitalized COVID-19 patients of the 1st wave demonstrating a cytokine storm and the exhaustion of most lymphocyte subpopulations. Herein, we describe the results obtained from COVID-19 patients of the 2nd wave. Read More

View Article and Full-Text PDF
September 2021

Do we need bamlanivimab? Is etesevimab a key to treating Covid-19?

Expert Opin Biol Ther 2021 Sep 24. Epub 2021 Sep 24.

Doggrell Biomedical Communications, 77 Wynnum North Rd, Wynnum, QLD 4178, Australia.

Introduction: Treatments for subjects with Covid-19 are required. One approach is neutralising monoclonal antibodies. Bamlanivimab and etesevimab are monoclonal antibodies to SARS-CoV-2. Read More

View Article and Full-Text PDF
September 2021

Sodium bicarbonate reduces the cooked hardness of lotus rhizome via side chain rearrangement and pectin degradation.

Food Chem 2021 Aug 26;370:130962. Epub 2021 Aug 26.

College of Food Science and Technology, Huazhong Agricultural University, Wuhan, Hubei 430070, China. Electronic address:

In this study, 0.1% (W/V) sodium bicarbonate (SB) solution was used to soften lotus rhizome, and the mechanism was characterized by monoclonal antibodies labeling (mAbs) and atomic force microscopy (AFM). The results showed that the cell wall of lotus rhizome was disintegrated under SB treatment. Read More

View Article and Full-Text PDF

Evaluation of the discriminatory potential of antibodies created from synthetic peptides derived from wheat, barley, rye and oat gluten.

PLoS One 2021 23;16(9):e0257466. Epub 2021 Sep 23.

Department of Food Science and Nutrition, Pavillon Paul-Comtois, Université Laval, Québec, Québec, Canada.

Celiac disease (CD) is triggered by ingestion of gluten-containing cereals such as wheat, barley, rye and in some cases oat. The only way for affected individuals to avoid symptoms of this condition is to adopt a gluten-free diet. Thus, gluten-free foodstuffs need to be monitored in order to ensure their innocuity. Read More

View Article and Full-Text PDF
September 2021

Chemiluminescence-Derived Self-Powered Photoelectrochemical Immunoassay for Detecting a Low-Abundance Disease-Related Protein.

Anal Chem 2021 Sep 23. Epub 2021 Sep 23.

Key Laboratory of Analytical Science for Food Safety and Biology (MOE & Fujian Province), Department of Chemistry, Fuzhou University, Fuzhou 350108, People's Republic of China.

Early diagnosis of cancers relies on the sensitive detection of specific biomarkers, but most of the current testing methods are inaccessible to home healthcare due to cumbersome steps, prolonged testing time, and utilization of toxic and hazardous substances. Herein, we developed a portable self-powered photoelectrochemical (PEC) sensing platform for rapid detection of prostate-specific antigen (PSA, as a model disease-related protein) by integrating a self-powered photoelectric signal output system catalyzed with chemiluminescence-functionalized Au nanoparticles (AuNPs) and a phosphomolybdic acid (PMA)-based photochromic visualization platform. TiO-g-CN-PMA photosensitive materials were first synthesized and functionalized on a sensor chip. Read More

View Article and Full-Text PDF
September 2021

From antibodies to living drugs: Quo vadis cancer immunotherapy?

Biol Futur 2021 Mar 1;72(1):85-99. Epub 2021 Feb 1.

Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, Egyetem tér 1., 4032, Debrecen, Hungary.

In the last few decades, monoclonal antibodies targeting various receptors and ligands have shown significant advance in cancer therapy. However, still a great percentage of patients experiences tumor relapse despite persistent antigen expression. Immune cell therapy with adoptively transferred modified T cells that express chimeric antigen receptors (CAR) is an engaging option to improve disease outcome. Read More

View Article and Full-Text PDF

Scientific memory from the early nineties; a common project with professors late János Gergely and Anna Erdei.

Biol Futur 2021 Mar 10;72(1):3-5. Epub 2021 Jan 10.

Department of Immunology, MTA-ELTE Immunology Research Group, Eötvös University, Budapest, Hungary.

Based on the findings of common project 29 years ago, the Scandinavian J. of Immunology accepted and published our paper entitled by "FcγR-Dependent Regulation of the Biosynthesis of Complement C3 by Murine Macrophages: the Modulatory Effect of IL-6" (Bajtay et al. in SJI 35:195-201, 1992). Read More

View Article and Full-Text PDF

Anifrolumab: First Approval.

Authors:
Emma D Deeks

Drugs 2021 Sep 23. Epub 2021 Sep 23.

Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.

Anifrolumab (anifrolumab-fnia; Saphnelo) is a monoclonal antibody antagonist of the type 1 interferon receptor (IFNAR). It is being developed by AstraZeneca (under license from Medarex, now Bristol-Myers Squibb) for the treatment of autoimmune disorders, including systemic lupus erythematosus (SLE) and lupus nephritis, the underlying pathogenesis of which involves type 1 interferon. In July 2021, intravenous anifrolumab was approved in the USA for the treatment of adult patients with moderate to severe SLE who are receiving standard therapy. Read More

View Article and Full-Text PDF
September 2021

Pharmacokinetics and Safety of Intravenous and Subcutaneous Auto-injector Single-dose Belimumab in Healthy Chinese Volunteers: A phase 1, Randomized, Open-label Study.

Rheumatol Ther 2021 Sep 23. Epub 2021 Sep 23.

Department of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center, Fudan University, 2901 Caolang Rd, Jinshan District, Shanghai, China.

Introduction: Belimumab is a recombinant human immunoglobulin G1λ monoclonal antibody indicated as an intravenous (IV) 10 mg/kg and subcutaneous (SC) 200-mg dose for the treatment of systemic lupus erythematosus (SLE). Belimumab 10 mg/kg IV has been approved for the treatment of patients with SLE in China. This phase 1 study investigated the pharmacokinetics (PK), safety, and tolerability of belimumab 200 mg SC and the approved IV formulation in a healthy Chinese population. Read More

View Article and Full-Text PDF
September 2021

Face atopic dermatitis resistant to dupilumab: a case series of three patients successfully treated with upadacitinib.

J Eur Acad Dermatol Venereol 2021 Sep 23. Epub 2021 Sep 23.

Dermatology Unit, Department of Mentals and Physical Health and Preventive medicine, University of Campania Luigi Vanvitelli Naples, Italy.

Atopic dermatitis (AD) is a frequent chronic inflammatory skin disease . Etiology is not known but a central role of IL-4 and 13 has been discovered . Dupilumab is a new monoclonal antibody approved for AD, it acts against subunit α of interleukin 4 receptor, blocking the signaling of IL-4 and 13. Read More

View Article and Full-Text PDF
September 2021

Isatuximab, carfilzomib and dexamethasone (Isa-Kd) for the management of relapsed multiple myeloma.

Future Oncol 2021 Sep 23. Epub 2021 Sep 23.

Department of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA 94143, USA.

The treatment of relapsed multiple myeloma remains challenging. Based on interim data from the randomized Phase III IKEMA study demonstrating a progression-free survival benefit with a combination of isatuximab (Isa, a CD38-targeted monoclonal antibody) and carfilzomib/dexamethasone (Kd) versus Kd alone, Isa-Kd recently received regulatory approval in the USA and Europe for patients with multiple myeloma who have received at least one prior line of therapy (in the USA, up to three prior lines). In this review we discuss the rationale and clinical trial experience to date with Isa-Kd. Read More

View Article and Full-Text PDF
September 2021

Discovery of Novel Small Molecule Inhibitors Disrupting the PCSK9-LDLR Interaction.

J Chem Inf Model 2021 Sep 23. Epub 2021 Sep 23.

Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, P. R. China.

Proprotein convertase subtilisin kexin 9 (PCSK9) has been identified as a reliable therapeutic target for hypercholesterolemia and coronary artery heart diseases since the monoclonal antibodies of PCSK9 have launched. Disrupting the protein-protein interaction (PPI) between PCSK9 and the low-density lipoprotein receptor (LDLR) has been considered as a promising approach for developing PCSK9 inhibitors. However, PPIs have been traditionally considered difficult to target by small molecules since the PPI surface is usually large, flat, featureless, and without a "pocket" or "groove" for ligand binding. Read More

View Article and Full-Text PDF
September 2021

Exploring the immune evasion of SARS-CoV-2 variant harboring E484K by molecular dynamics simulations.

Brief Bioinform 2021 Sep 22. Epub 2021 Sep 22.

Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.

Although the current coronavirus disease 2019 (COVID-19) vaccines have been used worldwide to halt spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the emergence of new SARS-CoV-2 variants with E484K mutation shows significant resistance to the neutralization of vaccine sera. To better understand the resistant mechanism, we calculated the binding affinities of 26 antibodies to wild-type (WT) spike protein and to the protein harboring E484K mutation, respectively. The results showed that most antibodies (~85%) have weaker binding affinities to the E484K mutated spike protein than to the WT, indicating the high risk of immune evasion of the mutated virus from most of current antibodies. Read More

View Article and Full-Text PDF
September 2021

Unique genotypic features of HIV-1 C gp41 membrane proximal external region variants during pregnancy relate to mother-to-child transmission via breastfeeding.

J Clin Pediatr Neonatol 2021 ;1(1):9-20

Molecular HIV Host Interaction Section, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, MD, USA.

Mother-to-child transmission (MTCT) through breastfeeding remains a major source of pediatric HIV-1 infection worldwide. To characterize plasma HIV-1 subtype C populations from infected mothers during pregnancy that related to subsequent breast milk transmission, an exploratory study was designed to apply next generation sequencing and a custom bioinformatics pipeline for HIV-1 gp41 extending from heptad repeat region 2 (HR2) through the membrane proximal external region (MPER) and the membrane spanning domain (MSD). MPER harbors linear and highly conserved epitopes that repeatedly elicits HIV-1 neutralizing antibodies with exceptional breadth. Read More

View Article and Full-Text PDF
January 2021